drugset / Trial / NCT02677805

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

NCT02677805

Phase 3 Completed 251 enrolled Croma-Pharma GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to assess the efficacy and safety of BoNT/a-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.

Timeline

Start
2016-03-30
Primary completion
2016-09-15
Completion
2017-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject letibotulinumtoxinA Protein / enzyme biologic 20 iu Intramuscular

Indications

No indication recorded.